The use of a threshold for cost-utility studies is of major importance to health authorities for
making the best allocation decisions for limited resources. Regarding the increasing number …

Background Venous thromboembolism (VTE) is a major global cause of morbidity and
mortality. Low molecular weight heparin (LMWH) and fondaparinux (FDP) are frequently …

Despite the central role of the threshold incremental cost-effectiveness ratio (ICER), or
lambda (λ), in the methods and application of cost-effective analysis (CEA), little attention …

Background The prescribing cascade model involves the misinterpretation of an adverse
reaction to 1 drug and the subsequent, potentially inappropriate prescription of a second …

Those making health care coverage decisions rely on health technology assessment (HTA)
for crucial technical information. But coverage decision-making, and the HTA that informs it …

Health technology is a pivotal locus of change and controversy in health care systems, and
The Problem of Health Technology offers a comprehensive and novel analysis of the topic …

As health costs in the US soar past $1.5 trillion, much evidence indicates that the nation
does not get good value for its money. It is widely agreed that we could do better by using …

Objectives To assess the feasibility of using a citizens' jury to elicit public values on health
technologies and to develop criteria for setting priorities for health technology assessment …

The cost‐effectiveness of new health care technologies is conditional upon who receives
what therapy and under what circumstances. Understanding this heterogeneity in cost …

Objective: The overarching question addressed in this article is: what has been the impact of
economic evidence to Canadian drug reimbursement decisions; within this, has an (explicit …